Ticker

60 Degrees Pharmaceuticals Inc. (NASDAQ: SXTP - Get Free Report) was the target of a significant decline in short interest during the month of March. As of March 31st, there was short interest totaling 160,681 shares, a decline of 66.9% from the March 15th total of 484,774 shares. Based on an average daily volume of 371,994

60 Degrees Pharmaceuticals Inc. (SXTP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

FY 2025 net product revenues increased 65% to $1,005,000 Current shelf capacity exhausted after raise of $4 million through an ATM facility WASHINGTON, March 31, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, reported today its financial results for the 2025 fiscal year ended…

60 Degrees files NDIN with FDA for Australian Chestnut Extract; May 25 decision deadline. FSU capsule license option expands commercialization strategy.

60 Degrees Pharmaceuticals Inc. (NASDAQ: SXTP) shares are down during Friday's premarket session. This follows a 9.6% decline, closing at $2.91 on Thursday.